comparemela.com

Latest Breaking News On - Jose oberholzer - Page 1 : comparemela.com

Type 1 diabetes: New cell therapy reduces need for insulin

The FDA has recently approved a cellular therapy for type 1 diabetes for the first 1. The therapy, called Lantidra, can reduce the need for insulin injections.

Zurich
Züsz
Switzerland
Arizona
United-states
Toni-isabella
Jose-oberholzer
Christiane-nasr
Zijian-chen
Matthewj-freeby
Celltrans-inc
School-of-medicine

A Startup Wins the First FDA Approval of a Cell Therapy for Type 1 Diabetes

A Startup Wins the First FDA Approval of a Cell Therapy for Type 1 Diabetes
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.

United-states
Chicago
Illinois
London
City-of
United-kingdom
University-of-illinois
American
Peter-marks
Eli-lilly
Jose-oberholzer
Vertex-pharmaceuticals

FDA Approves First Cell Therapy for Type 1 Diabetes in the US

FDA Approves First Cell Therapy for Type 1 Diabetes in the US
theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Peter-marks
Jose-oberholzer
American-diabetes-association
American-society-of-transplant-surgeons
University-of-illinois
Drug-administration
American-society-of-transplantation
Biologics-evaluation
Medications-are-also-coming
American-society

Researchers develop screening technique for Type 1 diabetes treatment

Houston, May 1: Getting a host immune system to accept the presence of implanted insulin-secreting cells could change the lives of the more than 700 million people who have Type 1 diabetes worldwide.

Houston
Texas
United-states
Rice-university
David-zhang
Omid-veiseh
Irfan-pathan
Boram-kim
Jose-oberholzer
Research-institute-of-texas
University-of-virginia
Nature-biomedical-engineering

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.